Author

Amnon Hoffman

Chairman, Division of Clinical Pharmacy Head, Pharm. D. Program, The Hebrew University of Jerusalem - Cited by 10,544 - PK-PD rationale for optimized DDS - including GRDF - PK and PD aspects of different peptide structures including cyclization of ac

Biography

Amnon Hoffman is a Professor for Bio-pharmacy and Clinical Pharmacy at the Institute of Drug Research, School of Pharmacy, Faculty of Medicine of the Hebrew University of Jerusalem (HUJI). He received his B. Pharm at 1977, MSc 1979 and PhD 1985 from HUJI. Postdoc in biopharmaceutics, at SUNY Buffalo. Since 1989 he was a Lecturer, Senior Lecturer in 1995 Associate Professor in 2002 and Full Professor in 2009 at HUJI, investigating the biopharmaceutical aspects of drug delivery systems (DDS)s and drug development. Prof. Hoffman is a worldwide expert in Pharmacokinetics and Pharmacodynamics. 
Title
Cited by
Year
Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects
I Cherniakov, AJ Domb, A HoffmanExpert opinion on drug delivery 12 (7), 1121-1133, 2051201
151
2015
Orally active peptides: is there a magic bullet?
AFB Räder, M Weinmüller, F Reichart, A Schumacher‐Klinger, ...Angewandte Chemie International Edition 57 (44), 14414-14438, 2018201
111
2018
Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration
I Cherniakov, D Izgelov, D Barasch, E Davidson, AJ Domb, A HoffmanJournal of Controlled Release 266, 1-7, 2017201
88
2017
The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol …
I Cherniakov, D Izgelov, AJ Domb, A HoffmanEuropean Journal of Pharmaceutical Sciences 109, 21-30, 2017201
87
2017
PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers
J Atsmon, I Cherniakov, D Izgelov, A Hoffman, AJ Domb, L Deutsch, ...Journal of Pharmaceutical Sciences 107 (5), 1423-1429, 2018201
76
2018
The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats
D Izgelov, E Shmoeli, AJ Domb, A HoffmanInternational journal of pharmaceutics 580, 119201, 2020202
56
2020
Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers
D Izgelov, E Davidson, D Barasch, A Regev, AJ Domb, A HoffmanEuropean Journal of Pharmaceutics and Biopharmaceutics 154, 108-115, 2020202
34
2020
Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol
C Itin, D Barasch, AJ Domb, A HoffmanInternational journal of pharmaceutics 581, 119276, 2020202
34
2020
cis‐Peptide Bonds: A Key for Intestinal Permeability of Peptides?
UK Marelli, O Ovadia, AO Frank, J Chatterjee, C Gilon, A Hoffman, ...Chemistry–A European Journal 21 (43), 15148-15152, 2015201
32
2015
Overcoming the lack of oral availability of cyclic hexapeptides: design of a selective and orally available ligand for the Integrin αvβ3
M Weinmüller, F Rechenmacher, U Kiran Marelli, F Reichart, TG Kapp, ...Angewandte Chemie International Edition 56 (51), 16405-16409, 2017201
30
2017
The effect of piperine pro-nano lipospheres on direct intestinal phase II metabolism: the raloxifene paradigm of enhanced oral bioavailability
D Izgelov, I Cherniakov, G Aldouby Bier, AJ Domb, A HoffmanMolecular Pharmaceutics 15 (4), 1548-1555, 2018201
25
2018
A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed/fasting states
C Itin, AJ Domb, A HoffmanExpert opinion on drug delivery 16 (10), 1031-1035, 2019201
25
2019
Enhancing oral bioavailability of cyclic RGD hexa-peptides by the lipophilic prodrug charge masking approach: redirection of peptide intestinal permeability from a paracellular …
A Schumacher-Klinger, J Fanous, S Merzbach, M Weinmüller, ...Molecular Pharmaceutics 15 (8), 3468-3477, 2018201
24
2018
The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration
D Izgelov, AJ Domb, A HoffmanEuropean Journal of Pharmaceutical Sciences 148, 105313, 2020202
15
2020
Development of a novel backbone cyclic peptide inhibitor of the innate immune TLR/IL1R signaling protein MyD88
S Dishon, A Schumacher, J Fanous, A Talhami, I Kassis, D Karussis, ...Scientific Reports 8 (1), 9476, 2018201
14
2018
Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo
R Reich, A Hoffman, RR Suresh, O Shai, J Frant, A Maresca, CT Supuran, ...Journal of Enzyme Inhibition and Medicinal Chemistry 30 (5), 767-772, 2015201
13
2015
Novel cannabinoid formulations
AJ Domb, A Hoffman, D IzgelovUS Patent App. 15/770,05, 2018201
9
2018
Oral aktive Peptide: Gibt es ein Patentrezept?
AFB Räder, M Weinmüller, F Reichart, A Schumacher‐Klinger, ...Angewandte Chemie 130 (44), 14614-14640, 2018201
9
2018
Myristoylation Confers Oral Bioavailability and Improves the Bioactivity of c(MyD 4–4), a Cyclic Peptide Inhibitor of MyD88
S Dishon, A Schumacher-Klinger, C Gilon, A Hoffman, G NussbaumMolecular pharmaceutics 16 (4), 1516-1522, 20120
9
2019
Formulation and method for increasing oral bioavailability of drugs
A Hoffman, AJ Domb, A Elgart, I CherniakovUS Patent App. 16/577,60, 2020202
9
2020

Referred From: https://scholar.google.com/citations?user=Wkp-9lAAAAAJ&hl=iw

Cited by
Citations 10544
h-index 56
i10-index 128
Recommended Journals
Open Access Journals